Newron Pharmaceuticals S.p.A. (ETR:NP5)

Market Cap	155.30M
Revenue (ttm)	51.39M
Net Income (ttm)	15.84M
Shares Out	n/a
EPS (ttm)	0.77
PE Ratio	9.80
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,801
Average Volume	5,939
Open	7.48
Previous Close	7.82
Day's Range	7.48 - 7.57
52-Week Range	6.03 - 11.90
Beta	0.67
RSI	47.93
Earnings Date	Apr 1, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the discovery and development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company’s product pipeline includes Evenamide, an add-on therapy for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 22
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: NP5